title: [Control of blood pressure morning surge in a Lebanese hypertensive population].
abstract: OBJECTIVE
  The primary endpoint of this prospective clinical study is to ascertain the degree of blood pressure control in the early-morning hours after 8 weeks of treatment with Telmisartan in hypertensive patients using home blood pressure measurements.
  
  
  METHODS
  Two hundred forty Lebanese patients with uncontrolled hypertension are enrolled in the study. The blood pressure is measured at the initial visit, then at week 4 of follow-up (optional visit) and after the 8 weeks period, by the physician at his office (with pulse rate) and by the patient at home in the morning.
  
  
  RESULTS
  The blood pressure measured by the patient at home in the morning has a mean value of 129.7/79.1 mmHg, significantly less than 135/85 mmHg (P < 10(-1)), and it is reduced by 31.9/13.5 mmHg (P < 10(-5)). At the physician's office, the reduction is 34.8/16 mmHg (P < 10(-4)). Heart rate is decreased by 4.7+/-0.5 bpm (P < 10(-5)). The drug was well tolerated.
  
  
  CONCLUSIONS
  This study has demonstrated that Telmisartan, by his long half-life, protects the patients against the early-morning hours blood pressure surge, period during which coronary and cerebral events are the most frequent.
authors.affiliation: Service de Cardiologie, Hôtel-Dieu de France, Faculté de Médecine, Université Saint-Joseph, Beyrouth, Liban. tamassih@usj.hdf.edu.lb
authors.forename: Tony
authors.initials: T
authors.lastname: Abdel-Massih
authors.forename: Nicolas
authors.initials: N
authors.lastname: Ibrahim
authors.forename: Antoine
authors.initials: A
authors.lastname: Sarkis
authors.forename: Georges
authors.initials: G
authors.lastname: Badaoui
authors.forename: Simon
authors.initials: S
authors.lastname: Abou-Jaoudé
authors.forename: Rabih
authors.initials: R
authors.lastname: Azar
authors.forename: Roland
authors.initials: R
authors.lastname: Kassab
authors.forename: Elie
authors.initials: E
authors.lastname: Salamé
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D018660:Blood Pressure Monitoring, Ambulatory; D002940:Circadian Rhythm / Q000502:physiology*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000077333:Telmisartan
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001565:Benzoates; D000077333:Telmisartan